Literature DB >> 15878645

Mucosal vaccination delays or prevents prion infection via an oral route.

F Goñi1, E Knudsen, F Schreiber, H Scholtzova, J Pankiewicz, R Carp, H C Meeker, R Rubenstein, D R Brown, M-S Sy, J A Chabalgoity, E M Sigurdsson, T Wisniewski.   

Abstract

In recent years major outbreaks of prion disease linked to oral exposure of the prion agent have occurred in animal and human populations. These disorders are associated with a conformational change of a normal protein, PrP(C) (prion protein cellular), to a toxic and infectious form, PrP(Sc) (prion protein scrapie). None of the prionoses currently have an effective treatment. A limited number of active immunization approaches have been shown to slightly prolong the incubation period of prion infection. Active immunization in wild-type animals is hampered by auto-tolerance to PrP and potential toxicity. Here we report that mucosal vaccination with an attenuated Salmonella vaccine strain expressing the mouse PrP, is effective at overcoming tolerance to PrP and leads to a significant delay or prevention of prion disease in mice later exposed orally to the 139A scrapie strain. This mucosal vaccine induced gut anti-PrP immunoglobulin (Ig)A and systemic anti-PrP IgG. No toxicity was evident with this vaccination approach. This promising finding suggests that mucosal vaccination may be a useful method for overcoming tolerance to PrP and preventing prion infection among animal and potentially human populations at risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15878645     DOI: 10.1016/j.neuroscience.2005.02.031

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  32 in total

1.  Clearance and prevention of prion infection in cell culture by anti-PrP antibodies.

Authors:  Joanna Pankiewicz; Frances Prelli; Man-Sun Sy; Richard J Kascsak; Regina B Kascsak; Daryl S Spinner; Richard I Carp; Harry C Meeker; Marcin Sadowski; Thomas Wisniewski
Journal:  Eur J Neurosci       Date:  2006-05       Impact factor: 3.386

Review 2.  The Ecology of Prions.

Authors:  Mark Zabel; Aimee Ortega
Journal:  Microbiol Mol Biol Rev       Date:  2017-05-31       Impact factor: 11.056

3.  Could immunomodulation be used to prevent prion diseases?

Authors:  Thomas Wisniewski; Fernando Goñi
Journal:  Expert Rev Anti Infect Ther       Date:  2012-03       Impact factor: 5.091

4.  Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease.

Authors:  Fernando Goñi; Candace K Mathiason; Lucia Yim; Kinlung Wong; Jeanette Hayes-Klug; Amy Nalls; Daniel Peyser; Veronica Estevez; Nathaniel Denkers; Jinfeng Xu; David A Osborn; Karl V Miller; Robert J Warren; David R Brown; Jose A Chabalgoity; Edward A Hoover; Thomas Wisniewski
Journal:  Vaccine       Date:  2014-12-21       Impact factor: 3.641

5.  Effect of transplantation of bone marrow-derived mesenchymal stem cells on mice infected with prions.

Authors:  Chang-Hyun Song; Osamu Honmou; Natsuo Ohsawa; Kiminori Nakamura; Hirofumi Hamada; Hidefumi Furuoka; Rie Hasebe; Motohiro Horiuchi
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

6.  A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell lines.

Authors:  Daryl Rhys Jones; William Alexander Taylor; Clive Bate; Monique David; Mourad Tayebi
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

Review 7.  Active and passive immunotherapy for neurodegenerative disorders.

Authors:  David L Brody; David M Holtzman
Journal:  Annu Rev Neurosci       Date:  2008       Impact factor: 12.449

8.  Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo.

Authors:  Martin J Sadowski; Joanna Pankiewicz; Frances Prelli; Henrieta Scholtzova; Daryl S Spinner; Regina B Kascsak; Richard J Kascsak; Thomas Wisniewski
Journal:  Neurobiol Dis       Date:  2009-05       Impact factor: 5.996

Review 9.  Cross currents in protein misfolding disorders: interactions and therapy.

Authors:  Rodrigo Morales; Kristi M Green; Claudio Soto
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-11       Impact factor: 4.388

10.  High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice.

Authors:  F Goñi; F Prelli; F Schreiber; H Scholtzova; E Chung; R Kascsak; D R Brown; E M Sigurdsson; J A Chabalgoity; T Wisniewski
Journal:  Neuroscience       Date:  2008-03-06       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.